Results of AGM

Hikma Pharmaceuticals Plc
25 May 2006



         Hikma Pharmaceuticals PLC - Results of Annual General Meeting

LONDON, 25 May 2006 - Hikma Pharmaceuticals PLC ('the Company') advises that at
its Annual General Meeting of shareholders, held at the London Underwriting
Centre, that began at 11.00am today, 25 May 2006, resolutions 1 to 12 contained
in the Notice of Annual General Meeting were passed as ordinary resolutions on a
show of hands, resolutions 13 and 14 were passed as special resolutions on a
show of hands, and resolution 15 was passed as an ordinary resolution by way of
a poll. The results of the poll are set out below:

Resolution 15                                  For          Against
Waiver of Rule 9 of the City Code on           36,581,606   2,561,802
Takeovers and Mergers

Copies of the resolutions dealing with special business passed at the Annual
General Meeting have been submitted to the UK Listing Authority for publication
through the Listing Authority's Document and Viewing Facility.

The total number of proxies received for each resolution is set out below.

Resolutions                                   For           Against    Vote 
                                                                       withheld
                                                                             
1 Receipt of accounts, together with          92,636,850    2,327,413  311,000
  reports of the Directors and auditors

2 Declaration of final dividend               95,275,263    -          -

3 Reappointment of Mr Samih Darwazah          91,748,810    3,240,853  285,600
  as a Director of the Company

4 Reappointment of Mr Mazen Darwazah          92,879,942    2,309,213  86,108
  as a Director of the Company
 
5 Reappointment of Mr Ali Al-Husry as a       95,257,063    18,200     -
  Director of the Company 

6 Reappointment of Mr Michael Ashton as a     95,275,263    -          -
  Director of the Company
                                                                    
7 Reappointment of Mr Breffni Byrne as a      95,275,263    -          -
  Director of the Company

8 Reappointment of Sir David Rowe-Ham as a    95,275,263    -          -
  Director of the Company
 
9 Reappointment of Deloitte & Touche as       95,037,639    90,528     147,096
  auditors of the Company

10 Authorise the Directors to set the         95,257,063    18,200      -
   remuneration of the auditors
                                                                    
11 Approval of the Board report on            89,267,907    2,930,733  3,076,623
   remuneration
                                                                    
12 Authorise the Directors to allot relevant  95,103,719    880        170,664
   securities up to an aggregate nominal
   amount of £5,559,947

13 Empower the Directors to allot equity      95,103,719    880        170,664
   securities for cash on a non pre-emptive
   basis up to an aggregate nominal amount of 
   £833,992
                                                                    
14 Cancellation of unissued unclassified      95,104,599    -          170,664
   shares
                                                                    
15 Waiver of Rule 9 of the City Code on       36,571,606    2,561,802  3,279,631
   Takeovers and Mergers  
                                                                     
The number of 10p ordinary shares in issue on 25 May 2006 was 167,287,607.

Waiver of Rule 9 of the City Code on Takeovers and Mergers

In relation to Resolution 15, at today's date, the total number of ordinary
shares held by the Concert Party, is 60,446,652, representing a combined
shareholding of 36.133% of the issued share capital of the Company. If all of
the options held by members of the Concert Party are exercised and the share
capital of the Company is not otherwise increased, the number of ordinary shares
held by the Concert Party will increase to 62,966,652, representing 37.081% of
the enlarged issued share capital of the Company.

Declaration of final dividend

The final dividend of 0.89 cents per share will be paid on 30 May 2006 to
shareholders on the register on 28 April 2006. Shareholders who are not resident
in Jordan have been given the option of receiving their dividend in Pounds
Sterling. The exchange rate in respect of this dividend is 1.8755 US dollars to
one Pound Sterling, equal to 0.47 pence per share. Shareholders resident in
Jordan have been given the opportunity to receive the dividend in Jordanian
Dinar, at a rate of 0.708 Jordanian Dinar per US dollar.

                                    - ENDS -




Enquiries:

Hikma Pharmaceuticals PLC

Henry Knowles                                     [phone]
Company Secretary
Susan Ringdal                                     [phone]
Investor Relations Director

Brunswick Group

Jon Coles / Wendel Verbeek / Justine McIlroy / Alex Tweed    [phone]

About Hikma

Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the United States,
the Middle East and North Africa ('MENA') region and Europe. In 2005, the Group
had revenue of $262 million and profit attributable to shareholders of $44
million. At 31 December 2005, the Group had over 1,800 employees. For news and
other information, please visit www.hikma.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange